Updated:
Amarin Corp PlcUK
Amarin Corp PlcUK was the London-listed shell of Amarin Corporation, the developer of Vascepa. Dissolved in 2012 after the group migrated to Ireland.
Amarin Corp PlcUK
AMARIN CORP PLCUK was incorporated in England and Wales as a public limited company, functioning historically as the London-listed vehicle for Amarin Corporation plc — an Irish-domiciled biopharmaceutical company focused on cardiovascular therapeutics. Amarin Corporation was originally founded in the UK in 1989 but re-domiciled to Ireland in 2010, with the UK PLC entity remaining as a legacy listing shell before its ultimate dissolution. The biopharmaceutical group behind the PLC is best known for developing Vascepa (icosapent ethyl), a purified ethyl ester of eicosapentaenoic acid derived from fish oil. The drug gained FDA approval for the treatment of severe hypertriglyceridemia in 2012, and later for cardiovascular risk reduction based on the landmark REDUCE-IT trial published in the New England Journal of Medicine (per NEJM, 2019). The listed Irish holding company consolidated all operational assets and intellectual property after its migration, leaving the UK PLC entity as a non-operational subsidiary. The PLC entity was formally dissolved via a voluntary striking-off from the Companies House register in England and Wales in 2012, contemporaneous with the group's completion of its migration to Ireland and its sole listing on NASDAQ under the ticker AMRN. No residual assets, liabilities, or investment portfolio remained within the UK PLC after this dissolution. The group had no private family-office investment mandate; it operated solely as a publicly listed pharmaceutical development and commercialization platform. Structurally, this entity represents a corporate migration artifact rather than a typical operating company or asset manager. The dual-listed architecture — once common for Irish-incorporated groups retaining a UK listing — was unwound as part of a broader simplification that concentrated Amarin's public-company presence on the NASDAQ Global Market.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
—
Corporate office
—
Frequently asked questions
What was the relationship between AMARIN CORP PLCUK and the NASDAQ-listed Amarin Corporation plc?
AMARIN CORP PLCUK was the London-listed predecessor and, for a period, a subsidiary of the Irish-incorporated Amarin Corporation plc, which now trades on NASDAQ under ticker AMRN. The PLC entity was used for an old London Stock Exchange listing of American Depositary Shares before the group centralized its corporate domicile and listing in Ireland and the United States respectively.
Does AMARIN CORP PLCUK still operate or invest as a going concern?
No. The UK entity was formally dissolved in 2012 via voluntary striking-off, according to Companies House records. It held no operational assets, investment portfolio, or staff at the time of dissolution. The biopharmaceutical business is now conducted entirely by the surviving Irish parent company.
Did AMARIN CORP PLCUK ever function as a family office or investment vehicle?
No. It was a publicly listed corporate shell tied to a single biopharmaceutical asset — the development and commercialization of Vascepa. It never operated as a private family office, nor did it manage a diversified investment portfolio or third-party capital.
Is there any connection between AMARIN CORP PLCUK and a wealth origin or family group?
None is publicly disclosed. Amarin Corporation was founded via traditional venture financing and public markets rather than with family-office backing, and the PLC entity was a purely corporate legal structure without ties to identifiable family wealth.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: